- Home
- DNTH vs ANAB Comparison
DNTH vs ANAB Comparison
Compare DNTH & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- ANAB
- Stock Information
- Founded
- DNTH 2015
- ANAB 2005
- Country
- DNTH United States
- ANAB United States
- Employees
- DNTH N/A
- ANAB N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- ANAB Health Care
- Exchange
- DNTH Nasdaq
- ANAB Nasdaq
- Market Cap
- DNTH 606.2M
- ANAB 621.1M
- IPO Year
- DNTH N/A
- ANAB 2017
- Fundamental
- Price
- DNTH $21.50
- ANAB $26.94
- Analyst Decision
- DNTH Strong Buy
- ANAB Buy
- Analyst Count
- DNTH 8
- ANAB 10
- Target Price
- DNTH $53.00
- ANAB $49.00
- AVG Volume (30 Days)
- DNTH 387.8K
- ANAB 515.6K
- Earning Date
- DNTH 08-07-2025
- ANAB 08-04-2025
- Dividend Yield
- DNTH N/A
- ANAB N/A
- EPS Growth
- DNTH N/A
- ANAB N/A
- EPS
- DNTH N/A
- ANAB N/A
- Revenue
- DNTH $6,524,000.00
- ANAB $111,872,000.00
- Revenue This Year
- DNTH N/A
- ANAB N/A
- Revenue Next Year
- DNTH N/A
- ANAB $24.39
- P/E Ratio
- DNTH N/A
- ANAB N/A
- Revenue Growth
- DNTH 102.36
- ANAB 387.20
- 52 Week Low
- DNTH $13.37
- ANAB $12.21
- 52 Week High
- DNTH $32.27
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- DNTH 61.73
- ANAB 66.30
- Support Level
- DNTH $19.90
- ANAB $25.48
- Resistance Level
- DNTH $22.49
- ANAB $28.50
- Average True Range (ATR)
- DNTH 1.43
- ANAB 1.26
- MACD
- DNTH 0.22
- ANAB 0.02
- Stochastic Oscillator
- DNTH 64.11
- ANAB 70.23
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).